All In Biotech

Free tool

FAERS Monitor: Yusimry

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761216 or its brand name (Yusimry, Adalimumab-Aqvh). Reports on generic versions are filed under their own applications.

Reports

99

Serious

25

25% of reports

Hospitalization

9

Death reported

2

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • accidental exposure to product34
  • product dose omission issue31
  • device malfunction28
  • no adverse event15
  • device leakage11
  • product quality issue9
  • product complaint6
  • drug ineffective5
  • device failure4
  • device issue4
  • incorrect dose administered4
  • pain4
  • product leakage4
  • device defective3
  • device difficult to use3

Reports by year received

View as table
YearReports
202323
202434
202525
202617

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,060 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
product leakageSignal4151.658.0457
device malfunctionSignal2884.761.92,239
accidental exposure to productSignal3470.153.42,258
device failureSignal455.821.4164
device leakageSignal1153.930.9521
product complaintSignal650.323.2243
device defectiveSignal336.812.172
product dose omission issueSignal3122.416.7621
no adverse eventSignal1517.611.0220
product quality issueSignal914.17.697
device difficult to useSignal39.63.215
device issueSignal49.53.623
incorrect dose administeredSignal43.71.46
pain41.40.50
drug ineffective50.80.30

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.